Proactive Investors - Run By Investors For Investors

Breakfast News - AIM Breakfast : Accesso Technology Group PLC, Amryt Pharmaceuticals, Bagir Group, Challenger Acquisitions Limited, Europa Oil & Gas (Holdings) Plc, PowerHouse Energy, Proxama PLC, Safestay

Breakfast News - AIM Breakfast : Accesso Technology Group PLC, Amryt Pharmaceuticals, Bagir Group, Challenger Acquisitions Limited, Europa Oil & Gas (Holdings) Plc, PowerHouse Energy, Proxama PLC, Safestay

What’s cooking in the IPO kitchen?

Arix Bioscience — Intention to float on the main market from the  global healthcare and life science company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management

Eco (Atlantic) Oil & Gas—Schedule One Update. Now expects admission ‘early February’.

Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.


Breakfast buffet

Bagir Group (LON:BAGR) 4p £12.4m

The designer, creator and provider of innovative tailoring, announced the conditional acquisition of the remaining 50% shareholding in Nazareth Garments, the joint venture owner of its manufacturing site in Nazareth, Ethiopia, for a total consideration of US$1.9 million. Eran Itzhak, Chief Executive Officer, commented, "The option to acquire the remaining 50% in this site giving us total control is timely as it coincides with the Company looking to expand production significantly and we can see growing interest in the site from our customer and prospective customer base as well as new exciting opportunities. There is still some way to go but we are in a good position to make Ethiopia a key cornerstone of our business."

Amryt Pharma (LON:AMYT) 17p £35.4m

The pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, announced positive results of a newly completed pre-clinical study that compared its drug compound AP102 (a somatostatin analogue therapy with the potential to treat acromegaly) with pasireotide, an approved product for treating patients with resistant acromegaly.  Amryt's AP102 did not demonstrate the potential to cause diabetes, an observation which, if replicated in clinical studies, could be clinically beneficial in treating acromegaly. “This suggests that it lacks the potential to cause or exacerbate diabetes, which is an issue with some other approved therapies.”  As previously reported, the Company is preparing AP102 for clinical trials in 2017.

Proxama (LON:PROX) 0.37p £7.94m

The international digital and mobile commerce company specialising in end-to-end payment solutions for card issuers and processors, announced that a leading South African insurance and financial services provider, has signed a 5 year contract with Proxama Solutions Limited for the supply of in-house EMV card issuing, PIN management and card lifecycle management. Revenue earned from software licenses, services and support will be £0.365m in 2017 and a minimum of £0.691m in total over the five years, with additional payments if certain card capacity thresholds are achieved.

Powerhouse Energy (LON:PHE) 1.03p £6.6m

Powerhouse has signed a Memorandum of Understanding  with Peel Environmental Ltd and its subsidiary, This is Protos LLP  to work together to pursue the development, construction and operation of an energy from waste plant at Peel Environmental’s Protos facility near Chester, UK.  This MOU was brokered by Waste2Tricity Ltd in conjunction with the joint development agreement between PowerHouse and Waste2Tricity announced on 18 January 2017.   The joint project envisages the construction of PowerHouse’s first commercial enterprise, utilising the Company’s G3-UHt system, at the Protos site together with a proposed plan for the delivery of five energy from  waste plants.  There is no certainty that the MOU will proceed to definitive agreements between the parties.

Challenger Acquisitions(LON:CHAL) 7.87p £1.8m

The Company has commenced a strategy to implement specific cost control measures and to actively manage the conversion of a portion of its outstanding convertible notes. Mark Gustafson, Chief Executive Officer of the Company, has agreed to a compensation arrangement of £1,000 per month until further notice. The board of directors has also been reduced to three members with the retirement of Markus Kameisis as an executive director. Mr. Kameisis retains his position as Chief Financial Officer of the Company. Going forward, the Company will continue to review public company costs to ensure these are minimised wherever possible.

Europa Oil & Gas (LON:EOG) 4.87p £11.94m

The UK and Ireland focussed exploration, development and production company’s wholly owned subsidiary has signed a Farm-Out Agreement (FOA) in relation to a 12.5% interest in the PEDL143 licence in the Weald Basin with a wholly owned subsidiary of Angus Energy Plc. Europa will retain a 20% interest in PEDL143 where a well targeting the 5.6mmbo conventional Holmwood prospect is anticipated to be drilled in 2017. FOA sees Europa fully carried to drill Holmwood. The 5.6mmbo prospective resources at Holmwood do not include an estimate for the Kimmeridge limestones that produced oil at Horse Hill.

Pebble Beach Systems Group (LON:PEB) 17.37p £21.65m

Trading update from software business specialising in solutions for the playout automation serving customers in the broadcast markets. Results for FY2016 are expected to be materially below the Board's previous expectations. There was a fall in performance at VCS which was due to the uncertainty caused by the lengthy sale process. In addition there are significant write offs to recognise the final sale price achieved. The bank increased the Company's facility to £17.8m in the weeks immediately prior to the sale.  It is not expected that the current level of bank financing will reduce before mid-March. The Board remains in regular dialogue with its bank, who remain supportive. FYDec16E £46.4m rev. £1.46m pre-tax loss.

Accesso Technology (LON:ACSO) 1545p £344.8m

The premier technology solutions provider to leisure, entertainment and cultural markets, announced that it expects Group revenues to be in line with expectations for the year ended  Dec 2016, and expects to be ahead of expectations with respect to profitability. This strong performance has been achieved despite significant and accelerated investment in product and infrastructure to support business and growth opportunities in geographies outside its traditional core markets, together with further investment in the recently launched accesso Prism wearable device. The Board is also pleased to report a strong start to 2017 where all accesso business lines are reporting good momentum.

Safestay (LON:SSTY) 45p £15.4m

The owner and operator of a new brand of contemporary hostel announced a trading update for the 12 months to 31 December 2016. The Group expects to report underlying EBITDA of £2.2m (2015: 0.6m) and revenues of £7.4m (2015: 4.0m). 2016 tough trading and Holland slow to start. That said, Safestay is a young growing business and its growth outlook remains unchanged for 2017. Advance bookings, for which the company has received deposits look strong compared to this time last year. FYDec16E £7.7m rev and £0.1m pre-tax loss rising to £8.3m and £0.4m profit in 2017.

Glenwick (LON:GWIK) 0.06p £1.32m

Glenwick has now entered non-binding heads-of-terms to acquire 100% of the share capital of Cora Gold Limited, which will constitute a new admission to trading under the AIM Rules. The Gold Portfolio consists of 10 highly prospective gold exploration properties totalling more than 1,600 km2 located in two significant gold areas, the Kenieba Window in Mali and Senegal and the Yanfolila Gold Belt in Mali. All share deal giving vemdors 91% of  enlarged capital. Additionally £130k raised at 0.05p supported by Paternoster Resources.

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use